The scientific landscape surrounding amyotrophic lateral sclerosis (ALS) continues to shift
as the number of genes associated with the disease risk and pathogenesis, and the cellular …

Amyotrophic lateral sclerosis (ALS) has historically posed unique challenges for gene-
therapy-based approaches, due to a paucity of therapeutic targets as well as the difficulty of …

Importance Intravenous edaravone is approved as a disease-modifying drug for patients
with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term …

Background In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS),
edaravone did not show a significant difference in the Revised ALS Functional Rating Scale …

Over the past decades, a multitude of experimental drugs have been shown to delay
disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but …

Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of
30,000 patients a year worldwide. The median reported survival time since onset ranges …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …

Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease, characterized
genetically by a disproportionately large contribution of rare genetic variation. Driven by …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons
and other neuronal cells, leading to severe disability and eventually death from ventilatory …

The concept of cell signaling in the context of nonenzyme-assisted protein modifications by
reactive electrophilic and oxidative species, broadly known as redox signaling, is a uniquely …